A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Part of paid clinical trials in Mobile, Alabama.

Sponsor
Bristol-Myers Squibb
Study ID
NCT06561386
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Specified dose on specified days
  • Relatlimab — DRUG
    Specified dose on specified days
  • Pembrolizumab — DRUG
    Specified dose on specified days
  • Carboplatin — DRUG
    Specified dose on specified days
  • Pemetrexed — DRUG
    Specified dose on specified days
  • Cisplatin — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

Key Dates

Start date
Oct 7, 2024
Status verified
May 2026
Primary completion
Jul 30, 2030
Completion
Aug 4, 2032

Study Design

Enrollment
1,000 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
  • Active Comparator: Arm B

Primary Outcome Measure

Overall survival (OS) in randomized participants with PD-L1 1% to 49% [ Time Frame: Up to 5 years ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (45)

FacilityCityStateZIPSite coordinators
Local Institution - 0487MobileAlabama36604
Site 0487
Southern Arizona VA Health Care SystemTucsonArizona85723
Thomas Hanzlik, Site 0368
580-792-1450
Local Institution - 0112Los AngelesCalifornia90404-
University of California Davis (UC Davis) Comprehensive Cancer CenterSacramentoCalifornia95817
Tianhong Li, Site 0304
718-555-1212
San Francisco Oncology AssociatesSan FranciscoCalifornia94115
Kevin Kim, Site 0159
415-885-8600
UCLA Hematology/Oncology - Santa MonicaSanta MonicaCalifornia90404
Edward Garon, Site 0111
310-926-5333
Local Institution - 0500Grand JunctionColorado81501
Site 0500
Local Institution - 0472WestminsterColorado80023
Site 0472
University of Miami Hospital and Clinics, Sylvester Cancer CenterMiamiFlorida33136
Estelamari Rodriguez, Site 0206
305-689-4059
Memorial Hospital WestPembroke PinesFlorida33028
Gelenis Domingo, Site 0162
000-000-0000
Florida Cancer Specialists - NorthSt. PetersburgFlorida33705
Mamta Choksi, Site 0358
727-842-8411
Local Institution - 0477TamaracFlorida33321
Site 0477
Florida Cancer Specialists - EastWest Palm BeachFlorida33401
Todd Gersten, Site 0360
561-366-4100
Affiliated Oncologists, LLCChicago RidgeIllinois60415
Rami Haddad, Site 0376
111111
Cancer Center of KansasWichitaKansas67214
Shaker Dakhil, Site 0251
316-262-4467
Saint Elizabeth Medical Center EdgewoodEdgewoodKentucky41017
Colleen Darnell, Site 0128
859-301-4000
Baptist Health LexingtonLexingtonKentucky40503
Firas Badin, Site 0130
859-260-6100
Local Institution - 0502PaducahKentucky42003
Site 0502
Local Institution - 0473Royal OakMichigan48073
Site 0473
Hattiesburg Clinic Hematology/OncologyHattiesburgMississippi39401-7233
John Hrom, Site 0226
601-261-1700
Local Institution - 0498Kansas CityMissouri64132
Site 0498
Local Institution - 0308BozemanMontana59715-
Renown Regional Medical CenterRenoNevada89502
Katharine Thomas, Site 0207
775-985-4000
Local Institution - 0346PatersonNew Jersey07503-
Local Institution - 0381AlbuquerqueNew Mexico87108-
Local Institution - 0356HawthorneNew York10532-
Veterans Affairs New York Harbor Healthcare SystemNew YorkNew York10016
Daniel Becker, Site 0392
212-523-4000
Local Institution - 0380NorthportNew York11768-
University of Rochester Medical CenterRochesterNew York14642
Arpan Patel, Site 0325
315-525-2102
SUNY Upstate Medical UniversitySyracuseNew York13210
Bhaskara Reddy Madhira, Site 0324
314-691-8862
Local Institution - 0357The BronxNew York10468-
Local Institution - 0352AshevilleNorth Carolina28806-
East Carolina UniversityGreenvilleNorth Carolina27858
Sameer Batoo, Site 0351
252-744-4929
Local Institution - 0369CantonOhio44708-
Local Institution - 0486CentervilleOhio45459
Site 0486
University of Cincinnati Medical CenterCincinnatiOhio45219
Jennifer Leddon, Site 0141
Local Institution - 0199ClevelandOhio44106-
Local Institution - 0366MassillonOhio44646-
Lancaster General Hospital - Ann B Barshinger Cancer InstituteLancasterPennsylvania17601
Samuel Kerr, Site 0272
717-215-9561
Texas Oncology - West TexasAbileneTexas79606
Pankaj Khandelwal, Site 0359
000-000-0000
Local Institution - 0305HarlingenTexas78550-
University of Texas MD Anderson Cancer CenterHoustonTexas77030
Mehmet Altan, Site 0378
203-809-3721
The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer CenterTylerTexas75701
Robert Droder, Site 0303
903-595-7093
Local Institution - 0302Salt Lake CityUtah84112
Site 0302
Local Institution - 0499LaceyWashington98503
Site 0499

Find similar trials in Mobile, AL

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Local Institution - 0487· Mobile, ALSouthern Arizona VA Health Care System· Tucson, AZLocal Institution - 0112· Los Angeles, CAUniversity of California Davis (UC Davis) Comprehensive Cancer Center· Sacramento, CASan Francisco Oncology Associates· San Francisco, CAUCLA Hematology/Oncology - Santa Monica· Santa Monica, CA

Related Studies